INTRODUCTION {#s1}
============

Berger and Hinglais firstly described IgA nephropathy (IgAN) in 1968, and it is a relatively newly recognized disease \[[@R1], [@R2]\]. In the next few decades, IgAN was considered as a common glomerulonephritis. At the initial time of the diagnosis of long-term prognosis, predicting is still difficult in this disease. There were four processes are as follows induce the renal injury in IgAN: (1) aberrant glycosylation of IgA1; (2) synthesis of antibodies directed against galactose-deficient IgA1; (3) binding of the galactose-deficient IgA1 by the anti-glycan/glycopeptide antibodies to form immune complexes; (4) accumulation of these complexes in the glomerular mesangium to initiate renal injury. Others consensual factors \[[@R3]--[@R5]\] include the occurrence of arterial hypertension, presence of severe lesions on initial renal biopsy, such as focal and segmental hyalinosis, and tubulointerstitial fibrosis. There also exist some other factors, such as age \[[@R6]\], sex, obesity or overweight, hyperuricemia or hypertriglyceridemia \[[@R7]\], and different immune genetic markers, all of the which are not extensively confirmed or controversial.

In IgAN patients, a previous study reported that Interleukin-6 (*IL-6*) contributed to the proliferation of cells \[[@R8]\]. *IL-6* encodes a cytokine that functions in inflammation and the maturation of B cells. And the encoded protein has turned out to be an endogenous pyrogen can induce fever in people who carried the infections or autoimmune diseases. The functioning of *IL-6* is associated with a variety of disease states, such as diabetes mellitus and systemic juvenile rheumatoid arthritis.

A study involved to patients with a progressive clinical course has reported that Increased *IL-6* glomerular expression as well as urinary excretion \[[@R9]\]. It has been suggested to be a prognostic marker for IgAN, but its role is still debated \[[@R10], [@R11]\]. At tumor sites, inflammatory cytokines can modulate the growth and invasive properties of tumor cells, and *IL-1* is part of the most potent pro-inflammatory cytokines \[[@R12]\]. *IL-1* exists in two agonistic forms, *IL-1*alpha and *IL*--beta (*IL-1B*). *IL-1B* coding for protein *IL1-β* is located in the 2q14 chromosome, has 7,153 kb and seven encoding regions. *IL-1B* plays a key role in the regulation of the immune responses and in the production of a variety of inflammatory mediators, together with other molecules \[[@R13]\].

In this study, we conducted an extensive association analysis to assess the roles of *IL-1B* and *IL-6* polymorphisms and haplotypes on susceptibility to IgAN in a Chinese Han population from a case-control study. A total of 10 single nucleotide polymorphisms (SNPs) were studied in this association analysis in an attempt to identify markers that might guide intervention decisions and improve patient survival.

RESULTS {#s2}
=======

A total of 880 participants, including 417 IgAN patients and 463 controls, were analyzed in this study. Basic patient characteristics (gender and age) are listed in Table [1](#T1){ref-type="table"}. 31.0% of the IgAN patients were men and 16.4% were women, while 30.1% of the controls were men and 22.5% were women. The mean ages were 33.22 ±12.15 years (mean ± SD) for IgAN patients and 50.65 ±11.79 years for controls.

###### Characteristics of cases and controls in this study

  Variable             Cases         Controls       P-Value
  -------------------- ------------- -------------- ---------------------
                       417(47.4%)    463(52.6%)     
  Gender                                            \< 0.012 (2-tailed)
   Male                273(31.0%)    265(30.1%)     
   Female              144(16.4%)    198(22.5%)     
  Age, yr (mean ±SD)   33.22±12.15   50.65 ±11.79   \< 0.000 (2-tailed)

10 SNPs in the *IL-1B* and *IL-6* gene were genotyped in the IgAN patients and the controls. Table [2](#T2){ref-type="table"} listed the basic characteristics of these SNPs in the study population. All of the ten SNPs have been conformed to HWE in the control group (*P* \> 0.05), and two-sided Pearson chi-square tests were used to identify differences in allele frequency distributions between IgAN patients and controls.

###### Frequency distributions of *TERT* alleles and their associations with IgAN risk

  SNP ID      Position    Gene      Role         Allele A\*/B   MAF     HWE *P*   OR (95% CI)   *^a^P*            *^b^P*      
  ----------- ----------- --------- ------------ -------------- ------- --------- ------------- ----------------- ----------- -----------
  rs2853550   113587121   *IL-1B*   Downstream   A/G            0.115   0.087     0.067         1.37(1.00-1.87)   **0.050**   0.50
  rs1143643   113588302   *IL-1B*   Intron       C/T            0.498   0.474     0.191         1.1(0.91-1.33)    0.320       1
  rs3136558   113591275   *IL-1B*   Intron       G/A            0.371   0.368     0.617         1.01(0.83-1.23)   0.890       1
  rs1143630   113591655   *IL-1B*   Intron       T/G            0.183   0.159     1             1.19(0.93-1.53)   0.169       1
  rs1143627   113594387   *IL-1B*   Promoter     G/A            0.528   0.481     0.160         1.2(1.00-1.45)    0.053       0.530
  rs16944     113594867   *IL-1B*   Promoter     A/G            0.528   0.476     0.162         1.23(1.02-1.48)   **0.031**   0.310
  rs1143623   113595829   *IL-1B*   Promoter     G/C            0.435   0.401     0.286         1.15(0.95-1.39)   0.149       1
  rs1800796   22766246    *IL-6*    Promoter     G/C            0.354   0.288     0.309         1.35(1.11-1.66)   **0.003**   **0.030**
  rs2069837   22768027    *IL-6*    Intron       G/A            0.216   0.189     0.097         1.18(0.94-1.49)   0.161       1
  rs2069840   22768572    *IL-6*    Intron       G/C            0.109   0.083     0.116         1.35(0.98-1.85)   0.066       1

**Abbreviations:** SNP = single nucleotide polymorphism, CI = confidence interval, HWE = Hardy-Weinberg Equilibrium, MAF = minor allele frequency, ORs = odds ratios.

**Notes:** \*Minor allele; ^a^*P* were calculated from two-sided Pearson chi-square tests for either allele frequency and ^b^*P* were adjusted by Bonferroni correction; *p*-value \< 0.05 indicates statistical significance.

The rs2853550 and rs16944 in *IL-1B*, and rs1800796 in *IL-6* were associated with 1.37-fold (95% CI, 1.00-1.87, *P* = 0.050), 1.23-fold (95% CI, 1.02-1.48, *P* = 0.031), and 1.33-fold (95% CI, 1.11-1.66, *P* = 0.003) increases in the risk of developing IgAN, respectively. The SNP rs2853550 had a weak significant difference. Only one (rs1800796) of the three SNPs was still correlated with IgAN in the allelic model after Bonferroni correction.

And then, we determined the association between these 10 SNPs and IgAN risk using four genetic models (Table [3](#T3){ref-type="table"}); *P*-values were calculated using the chi-square test. The "A/G-A/A" genotype at the rs2853550 SNP increased the risk of IgAN in the dominant model (OR = 1.46; 95% CI, 1.04-2.05, *P* = 0.030), and "A/G" in the overdominant model with a P = 0.023 (OR = 1.151; 95%CI, 1.06 -- 2.15). The "G" allele in rs16944 decreased the IgAN risk in the log-additive model (OR = 0.80; 95% CI, 0.66-0.97, *P* = 0.026). However, these results were no statistical significance after adjustments for age and gender and the Bonferroni correction.

###### Genotypic model analysis of relationship between SNPs and IgAN risk

  SNP-ID         Model         Genotype      Case (n, %)        Control (n, %)     Without adjustment   With adjustment                                  
  -------------- ------------- ------------- ------------------ ------------------ -------------------- ------------------ -------------- -------------- -----------
  rs2853550      Codominant    G/G           387 (84.1%)        327 (78.4%)        1                    0.075              1              0.140          0.60
  A/G            66 (14.3%)    84 (20.1%)    1.51 (1.06-2.15)   1.55 (1.00-2.40)                                                                         
  A/A            7 (1.5%)      6 (1.4%)      1.01 (0.34-3.05)   0.80 (0.19-3.38)                                                                         
  Dominant       G/G           387 (84.1%)   327 (78.4%)        1                  **0.030**            1                  0.072          0.36           
  A/G-A/A        73 (15.9%)    90 (21.6%)    1.46 (1.04-2.05)   1.47 (0.96-2.26)                                                                         
  Recessive      G/G-A/G       453 (98.5%)   411 (98.6%)        1                  0.920                1                  0.680          1              
  A/A            7 (1.5%)      6 (1.4%)      0.94 (0.31-2.83)   0.74 (0.18-3.12)                                                                         
  Overdominant   G/G-A/A       394 (85.7%)   333 (79.9%)        1                  **0.023**            1                  **0.048**      0.24           
  A/G            66 (14.3%)    84 (20.1%)    1.51 (1.06-2.15)   1.51 (1.06-2.15)                                                                         
  Log-additive   \-\--         \-\--         \-\--              1.35 (0.99-1.83)   0.056                1.34 (0.92-1.97)   0.130          0.650          
  rs16944        Codominant    A/A           97 (20.9%)         110 (26.5%)        1                    0.082              1              0.460          1
  G/A            247 (53.4%)   218 (52.5%)   0.78 (0.56-1.08)   0.83 (0.55-1.25)                                                                         
  G/G            119 (25.7%)   87 (21%)      0.64 (0.44-0.95)   0.74 (0.45-1.20)                                                                         
  Dominant       A/A           97 (20.9%)    110 (26.5%)        1                  0.053                1                  0.270          1              
  G/A-G/G        366 (79%)     305 (73.5%)   0.73 (0.54-1.00)   0.80 (0.54-1.19)                                                                         
  Recessive      A/A-G/A       344 (74.3%)   328 (79%)          1                  0.098                1                  0.380          1              
  G/G            119 (25.7%)   87 (21%)      0.77 (0.56-1.05)   0.84 (0.57-1.24)                                                                         
  Overdominant   G/G-A/A       197 (47.5%)   216 (46.6%)        1                  0.81                 1                  0.84           1              
  G/A            218 (52.5%)   247 (53.4%)   0.97 (0.74-1.26)   0.97 (0.69-1.34)                                                                         
  Log-additive   \-\--         \-\--         \-\--              0.80 (0.66-0.97)   **0.026**            0.86 (0.67-1.10)   0.220          0.880          
  rs1800796      Codominant    C/C           239 (51.6%)        176 (42.4%)        1                    **0.014**          1              **0.003**      **0.012**
  C/G            181 (39.1%)   184 (44.3%)   1.38 (1.04-1.83)   1.70 (1.19-2.43)                                                                         
  G/G            43 (9.3%)     55 (13.2%)    1.74 (1.11-2.71)   2.03 (1.17-3.53)                                                                         
  Dominant       C/C           239 (51.6%)   176 (42.4%)        1                  **0.006**            1                  **9.00E-04**   **3.2 E-03**   
  C/G-G/G        224 (48.4%)   239 (57.6%)   1.45 (1.11-1.89)   1.77 (1.26-2.48)                                                                         
  Recessive      C/C-C/G       420 (90.7%)   360 (86.8%)        1                  0.063                1                  0.089          0.356          
  G/G            43 (9.3%)     55 (13.2%)    1.49 (0.98-2.28)   1.57 (0.93-2.66)                                                                         
  Overdominant   C/C-G/G       231 (55.7%)   282 (60.9%)        1                  0.12                 1                  **0.023**      0.115          
  C/G            184 (44.3%)   181 (39.1%)   1.24 (1.10-1.62)   1.48 (1.05-2.07)                                                                         
  Log-additive   \-\--         \-\--         \-\--              1.34 (1.10-1.63)   **0.004**            1.51 (1.18-1.94)   **0.001**      **0.004**      

**Abbreviations:** CI = confidence interval, OR = odds ratio, SNP = single nucleotide polymorphism.

**Notes:** *p-*values were calculated by *Wald* test and *p-*value \< 0.05 indicates statistical significance;

^a^*P* were adjusted by gender and age and ^b^*P* were adjusted by Bonferroni correction.

For the rs1800796 SNP, the "G" allele increased the risk 1.38-fold (95% CI, 1.04-1.83; *P* = 0.014) in the codominant model, the "C/G-G/G" genotype increased the risk of IgAN 1.45-fold (95% CI, 1.11-1.89; *P* = 0.006) in the dominant model, and the "G" allele increased the risk 1.34-fold (95% CI, 1.10-1.63; *P* = 0.004) in the log-additive model. In addition, after adjustment for age and gender, the "G" allele increased the IgAN risk 1.70-fold (95% CI, 1.19-2.43; *P* = 0.003) in the codominant model, the "C/G-G/G" genotype increased the risk of IgAN more than 1.70-fold (95% CI, 1.26-2.48; *P* = 9.00E-04) in the dominant model, and the "G" allele increased the risk more than 1.50-fold (95% CI, 1.18-1.94; *P* = 0.001) in the log-additive model. In the overdominant model, "C/G" increased the risk by 1.48-fold (P = 0.023) adjusted by gender and age. According to the adjusted by Bonferroni correction, mutations at rs1800796 (codominant *P* = 0.012; dominant P = 3.2 E-03; additive *P* \< 0.004) were still associated with an increased IgAN risk.

*IL-1B* and *IL-6* genetic polymorphisms were characterized utilizing the haplotype and linkage disequilibrium (LD) analyses. LD was determined pairwise among all these 10 SNPs, the haplotype structure of the two genes were analyzed, two blocks (Figure [1](#F1){ref-type="fig"}) were detected in studied *IL-1B* SNPs and one block (Figure [2](#F2){ref-type="fig"}) was found in IL-6 SNPs by haplotype analyses.

![Linkage disequilibrium patterns of 7 SNPs in *IL-1B*](oncotarget-08-71750-g001){#F1}

![Linkage disequilibrium patterns of three SNPs in *IL-6*](oncotarget-08-71750-g002){#F2}

Finally, a haplotype-based association study was performed to examine associations between *IL-1B* and *IL-6* haplotype and risk of IgAN (Table [4](#T4){ref-type="table"}), and P-values were calculated using the Wald test. Altogether we detected that there were 11 haplotypes in the two genes and only two haplotypes (G~rs1800796~A ~rs2069837~G ~rs2069840~ and G ~rs1800796~A ~rs2069837~C~rs2069840~) were found to increase risk of suffering from IgAN by more than 1.40-fold (95 % CI, 1.02 - 1.95; *P* = 0.037) and 1.90-fold (95 % CI, 1.03 - 3.60; *P* = 0.042), respectively. After adjusting for age and gender, the "G~rs1800796~A ~rs2069837~G ~rs2069840~" (95% CI, 1.05 - 2.40; *P* = 0.027) and "G~rs1800796~A~rs2069837~C~rs2069840~" (95% CI, 1.09 - 5.02; *P* = 0.029) haplotypes increased the IgAN risk 1.59- fold and 2.34-fold, respectively. Interestingly, for "G~rs1800796~G~rs2069837~C~rs2069840~", there existed a statistically significant difference (OR = 1.39; 95% CI, 1.04 - 1.87; *P* = 0.026) after adjusting for age and gender.

###### Haplotype analysis results in this study

              rs2853550\|rs1143643                          Freq    Without adjustment   With adjustment                        
  ----------- --------------------------------------------- ------- -------------------- ----------------- -------------------- -----------
  Haplotype   G\| T                                         0.515   1                    \-\--             1                    \-\--
              G\| C                                         0.385   1.04 (0.85 - 1.28)   0.680             1.02 (0.79 - 1.31)   0.900
              A\| C                                         0.100   1.37 (0.99 - 1.88)   0.055             1.35 (0.90 - 2.01)   0.140
              rs1143630\| rs1143627\| rs16944\| rs1143623                                                                       
              G\| A\| G\| C                                 0.497   1                    \-\--             1                    \-\--
              G\| G\| A\| G                                 0.247   1.15 (0.91 - 1.45)   0.250             1.08 (0.81 - 1.45)   0.590
              T\| G\| A\| G                                 0.168   1.31 (1.00 - 1.71)   0.053             1.21 (0.86 - 1.69)   0.270
              G\| G\| A\| C                                 0.082   1.39 (0.97 - 2.00)   0.076             1.33 (0.85 - 2.08)   0.220
              rs1800796\| rs2069837\| rs2069840                                                                                 
              C\| A\| C                                     0.677   1                    \-\--             1                    \-\--
              G\| G\| C                                     0.198   1.25 (0.99 - 1.58)   0.062             1.39 (1.04 - 1.87)   **0.026**
              G\| A\| G                                     0.096   1.41 (1.02 - 1.95)   **0.037**         1.59 (1.05 - 2.40)   **0.027**
              G\| A\| C                                     0.025   1.92 (1.03 - 3.60)   **0.042**         2.34 (1.09 - 5.02)   **0.029**

**Abbreviations:** CI = confidence interval, OR = odds ratio, SNP = single nucleotide polymorphism.

**Notes:** *p*-values were calculated by *Wald* test and *p*-value \< 0.05 indicates statistical significance;

\*Adjusted by gender and age.

DISCUSSION {#s3}
==========

The onset of IgAN may be associated with infections in the upper respiratory tract. Genetic analysis of familial IgAN is the most promising approach to the identification of IgA disease \[[@R14], [@R15]\]. For example, a recently study reported that 30 IgAN families were analyzed utilizing the whole-genome scanning \[[@R16]\]. However, in IgAN it is still not understood how the composition of circulating immune complexes affects the disease presentation, severity, and/or progression. Five novel variants were correlated with a protective effect against IgAN susceptibility were identified in a Genome-wide study \[[@R17]\]. It was reported that people carried protective alleles and had the lowest prevalence of IgAN in African populations. But in Asians, it was reported that people have fewer protective variants and have the highest prevalence. In a genome-wide linkage analysis study with 30 multiplex kindreds, had demonstrated the linkage of IgAN to 6q22--23 \[[@R16]\].

There is no doubt that there exist genetic components to the IgAN pathogenesis and IgAN clinical expression. In ourstudy, we systematically examined the impact of 10 SNPs in the *IL-1B* and *IL-6* loci on susceptibility to IgAN. We identified the association between SNPs and the susceptibility of esophageal cancer in five genetic models (codominant, dominant, recessive, overdominant and additive), which equivalent of repeated multiple comparisons, increasing the chance of making type I errors. Meanwhile, we should perform the *P* correction with Bonferroni correction. We found that the rs2853550, rs16944 in *IL-1B* and rs1800796 in *IL-6* genetic polymorphisms were correlated with an increased the IgAN risk in a northwestern Chinese Han patients population. To the best of our knowledge, this is the first case-control study to investigate this association. Persistent inflammation is linked with cancer development and progression \[[@R18]\]. *IL1-B*, a key cytokine released from glial cells, is critically involved in the pathogenesis of chronic pain \[[@R19]\], memory deficit \[[@R20]\], via activation of IL-1R1 \[[@R21]\]. It has revealed that treatment with *IL1B* can promote the invasiveness of breast cancer (BC) cells *in vitro* \[[@R22], [@R23]\]. A study reported that *IL1B* induced osteoprotegerin secretion, independent of BC subtype and basal osteoprotegerin levels \[[@R24]\]. The polymorphism rs1143630 is located in intron four, a noncoding region of the *IL1B* gene. Many articles refer to associations in intronic regions and risk of diseases \[[@R25]\]. The SNP rs1143630 of *IL1B* in the additive model considering the "T" allele as risk showed association with the preeclamptic event \[[@R26]\]. In our study, we detected that the SNP rs1143630 was not associated with IgAN risk. For rs1143633, there existed the significant difference between patients with schizophrenia and controls, and also found a association between rs16944 polymorphisms and female patients with schizophrenia in a Japanese population \[[@R27]\]. In this article, the results we get showed that rs16944 polymorphism increased in the risk of developing IgAN.

GQ Sun et al. \[[@R28]\] found that the *IL-6* rs1800795 G\>C polymorphisms presented an increased risk in dominant and recessive models, but they did not find that the IL-6 rs1800796 CC were correlated with an increased risk of coronary artery disease. A study reported that the rs1800796 TT genotype was associated with increased the susceptibility of cerebral thrombosis in the Chinese population \[[@R29]\]. Previous meta-analysis demonstrated significant association between rs1800796 of IL6 and cancer risk, with the allele G as a risk allele \[[@R30]\]. The frequency of GG genotype of rs2069837 was higher in hepatocellular carcinoma patients, compared with controls (P \< 0.05) \[[@R31]\]. In our current study, we for the first time studied the correlations between three SNPs (rs1800796, rs2069837 and rs2069840) in *IL-6* gene and IgAN susceptibility in a Chinese population. Rs1800796 SNP was associated with IgAN risk, rs2069837 and rs2069840 showed no correlations with IgAN susceptibility. Further studies should involve some others regions and ethnic groups. None of previous study found that IL-6 haplotype was directly associated with IgAN risk. Our study detected that haplotype "Grs~1800796~A~rs2069837~G~rs2069840~" and "G~rs1800796~Ars~2069837~C~rs2069840~" are related with the IgAN increasing risk.

Some limitations of the present study should be considered when interpreting the results. First, Several risk factors, such asgender, absence of macrohematuria, hypertension, severe proteinuria, smoking, and histopathologic changes, had been described to be associated with a poor outcome \[[@R32]\]. But in our articles, we only considered age and age, the further studies should collect more details of the clinical information. Second, the associations between the two genes (*IL-1B* and *IL-6*) polymorphisms and clinic pathological disease type were not evaluated in this study, Finally, both IgAN patients and controls were enrolled at the same hospital and therefore it may not be representative of the general population. Additional studies are needed to clarify the genetic mechanisms underlying IgAN by fine-mapping the susceptibility regions of the variants.

In conclusion, we demonstrated that the *IL-1B* and *IL-6* genetic polymorphisms are associated with an increasing risk of IgAN in a Chinese case-control population. This study offers new information on the relationship between two genes (*IL-1B* and *IL-6*) polymorphisms and IgAN susceptibility. Moreover, this study reveals the molecular markers associated with of IgAN susceptibility and could therefore be used as diagnostic and prognostic.

MATERIALS AND METHODS {#s4}
=====================

Ethics and consent {#s4_1}
------------------

All subjects were informed of the purpose of the study and the experimental procedures involved. The study protocol was approved by the ethics committee of the First Affiliated Hospital of Xi\'an Jiaotong University. We also obtained signed informed consent from all participants. The experimental protocol was implemented in accordance with the approved guidelines.

Study participants {#s4_2}
------------------

From August 2012 to July 2016, 417 patients (273 males and 114 females, mean age of 33.22±12.15) were recruited to participates form Han population in the northwest China, all the cases were diagnosed as IgAN by renal biopsy and none-familialy IgAN cases. 463 healthy subjects (265 males and 198 females, mean age of 50.65 ±11.79) were recruited from routine healthy examinations in the same hospitals. All subjects were unrelated Chinese Han people living in Xi\'an city or nearby. There are detail inclusion/exclusion criteria: patients with cancer, infection, secondary IgAN (Secondary IgAN is seen most commonly in patients with liver disease or mucosal inflammation, in particular affecting the gastrointestinal tract), other renal diseases and autoimmune diseases were excluded. The exclusion criteria for healthy subjects included the chronic disease, central nervous system-related disease, and conditions involving vital organs (liver, heart, lung, brain) and more aggressive metabolic and endocrinological disease.

SNP selection and genotyping {#s4_3}
----------------------------

We examined 7 SNPs in *IL-1B* and 3 SNPs in *IL-6*, and all of the 10 SNPs had minor allele frequencies (MAF) greater than 5%. Samples were centrifuged and stored at −80° until analysis. We extracted genomic DNA from peripheral blood samples using the GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag Ltd. Xi\'an, China) according to the manufacturer\'s protocol and measured DNA concentrations using a NanoDrop 2000. Sequenom MassARRAY Assay Design 3.0 Software was used to design primers for amplification and extension reactions \[[@R33]\]. SNP genotyping was performed using a Sequenom MassARRAY RS1000 according to the manufacturer\'s standard protocol \[[@R33]\]. Finally, Sequenom Typer 4.0 Software was used for data management and analysis \[[@R33], [@R34]\].

Statistical analysis {#s4_4}
--------------------

Departure from Hardy-Weinberg Equilibrium (HWE) was assessed for the frequency of each SNP in genotype frequencies between the esophageal cancer and control groups were evaluated using the Chi-square test \[[@R35]\]. Microsoft Excel and the SPSS 17.0 statistical package (SPSS, Chicago, IL) were used for statistical analyses. All P-values presented in this study are two-sided; P ≤ 0.05 was considered statistically significant. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using unconditional logistic regression analyses \[[@R36]\]. The web-based software SNP Stats was used to identify associations between SNPs and the risk of esophageal cancer in four genetic models (Codominant, dominant, recessive, and additive) \[[@R37]\]. We used the Haploview software package (version 4.2) and the SHEsis software platform (<http://analysis.bio-x.cn/myAnalysis.php>) to analyze linkage disequilibrium, haplotype construction, and genetic associations at polymorphism loci \[[@R38], [@R39]\].
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